S16, S17)
Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cunod M, Buclin T, Do KQ:Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients
Boosts energy levels and brain function Strengthens immune system and bones Reduces stress and anxiety Improved hair, skin and nail health Better metabolism and weight management Enhanced sleep quality Elipsa provides a soothing, relaxing, non-invasive, and therapeutic treatment that can be administered independently or combined with other treatments and services to elevate results
In the UK, the regulatory pathway for new medicines requires submission of a Marketing Authorisation Application (MAA) to the MHRA